27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- The German Ministry of Education & Research and the Ministry of Health have granted €43.7 million to InflaRx N.V. (NASDAQ:IFRX) to support the development of vilobelimab for COVID-19 patients.
- The grant was awarded as part of a government initiative, which the German Federal Government announced earlier this year, to accelerate the development of promising therapeutic options for treating COVID-19 in patients at all stages of the disease.
- The initial tranche of €25.8 million (approximately $29.9 million) is structured as reimbursement of 80% of certain pre-specified expenses related to the clinical development and manufacturing of vilobelimab.
- The remainder of the grant will be awarded in three additional tranches, each conditional on reaching agreed-upon development and manufacturing-related milestones.
- Payments from this grant to the Company are expected to begin in Q4 2021.
- The Phase 3 part of Phase 2/3 study with vilobelimab in critically ill, mechanically ventilated COVID-19 patients has been fully enrolled. Top-line results are expected in Q1 of 2022.
- Related: InflaRx's Vilobelimab Shows Encouraging Signs Of Drug Activity In Mid-Stage Study With Dermatological Ulcer Patients.
- Price Action: IFRX shares are up 13.60% at $2.75 during the market session on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!